


CLAIMS


1. A pyrazole derivative represented by the following general formula:



wherein

R¹ represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from



, and the other represents a group represented by the formula:
 -Z-Ar wherein Ar represents a C₆₋₁₀ aryl group which may have the
 same or different 1 to 3 groups selected from the following
 5 substituent group (B) or a C₁₋₉ heteroaryl group which may have
 the same or different 1 to 3 groups selected from the following
 substituent group (B); and Z represents -O-, -S- or -NY- (in
 which Y represents a hydrogen atom or a C₁₋₆ alkyl group), an
 aliphatic cyclic amino group which may have the same or different
 10 1 to 3 groups selected from the following substituent group (A),
 or an aromatic cyclic amino group which may have the same or
 different 1 to 3 groups selected from the following substituent
 group (B);

R represents a C₃₋₈ cycloalkyl group which may have the
 15 same or different 1 to 3 groups selected from the following
 substituent group (A), a C₆₋₁₀ aryl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 group (B), a C₂₋₉ heterocycloalkyl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 20 group (A), or a C₁₋₉ heteroaryl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo
 25 group, -G¹, -OG², -SG², -N(G²)₂, -C(=O)G², -C(=O)OG², -C(=O)N(G²)₂,

-S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹, -OC(=O)G¹,
 -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹ and
 -C(=O)NHS(=O)₂G¹;

[substituent group (B)]:

5 a halogen atom, a nitro group, a cyano group, -G¹, -OG²,
 -SG², -N(G²)₂, -G³OG⁴, -G³N(G⁴)₂, -C(=O)G², -C(=O)OG², -C(=O)N(G²)₂,
 -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹, -OC(=O)G¹,
 -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹ and
 -C(=O)NHS(=O)₂G¹;

10 in the above substituent group (A) and/or (B),

 G¹ represents a C₁₋₆ alkyl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 group (C), a C₂₋₆ alkenyl group which may have the same or different
 1 to 3 groups selected from the following substituent group (C),
 15 a C₂₋₆ alkynyl group which may have the same or different 1 to
 3 groups selected from the following substituent group (C), a
 C₃₋₈ cycloalkyl group which may have the same or different 1 to
 3 groups selected from the following substituent group (C), a
 C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups
 20 selected from the following substituent group (D), a C₂₋₉
 heterocycloalkyl group which may have the same or different 1
 to 3 groups selected from the following substituent group (C),
 or a C₁₋₉ heteroaryl group which may have the same or different
 1 to 3 groups selected from the following substituent group (D);

25 G² represents a hydrogen atom, a C₁₋₆ alkyl group which
 may have the same or different 1 to 3 groups selected from the
 following substituent group (C), a C₂₋₆ alkenyl group which may

have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G² may be the same or different when there are 2 or more G² in the substituents;

G³ represents a C₁₋₆ alkyl group;

G⁴ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G⁴ may be the same or different when there are 2 or more G⁴ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and

[substituent group (D)]:


a halogen atom, a nitro group, a cyano group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶,

-S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂,
 -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵;
 in the substituent group (C) and/or (D),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a
 5 C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉
 heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆
 alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀
 aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl
 10 group, and with the proviso that G⁶ may be the same or different
 when there are 2 or more G⁶ in the substituents, or a
 pharmaceutically acceptable salt thereof or a prodrug thereof.

2. A pyrazole derivative as claimed in claim 1, wherein Q
 15 represents a group represented by the formula: -Z-Ar¹ wherein Ar¹
 represents a C₆₋₁₀ aryl group which may have the same or different
 1 to 3 groups selected from the following substituent group (B);
 and Z represents -O-, -S- or -NY- (in which Y represents a hydrogen
 atom or a C₁₋₆ alkyl group), an aliphatic cyclic amino group which
 20 may have the same or different 1 to 3 groups selected from the
 following substituent group (A), or an aromatic cyclic amino
 group which may have the same or different 1 to 3 groups selected
 from the following substituent group (B); T represents a group
 selected from



; R represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (B)]:

5 a halogen atom, a nitro group, a cyano group, -G¹, -OG², -SG², -N(G²)₂, -G³OG⁴, -G³N(G⁴)₂, -C(=O)G², -C(=O)OG², -C(=O)N(G²)₂, -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹, -OC(=O)G¹, -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹ and -C(=O)NHS(=O)₂G¹;

10 in the above substituent group (B),

G¹ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C),
 15 a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups
 20 selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

25 G² represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may

have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G² may be the same or different when there are 2 or more G² in the substituents;

G³ represents a C₁₋₆ alkyl group;

G⁴ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G⁴ may be the same or different when there are 2 or more G⁴ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶,

-S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂,
 -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵;
 in the substituent group (C) and/or (D),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a
 5 C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉
 heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆
 alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀
 aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl
 10 group, and with the proviso that G⁶ may be the same or different
 when there are 2 or more G⁶ in the substituents, or a
 pharmaceutically acceptable salt thereof or a prodrug thereof.

3. A pharmaceutical composition comprising as an active
 15 ingredient a pyrazole derivative as claimed in claim 1 or 2,
 or a pharmaceutically acceptable salt thereof or a prodrug
 thereof.

4. A pharmaceutical composition as claimed in claim 3, wherein
 20 the composition is a sodium/glucose cotransporter inhibitor.

5. A pharmaceutical composition as claimed in claim 3 or 4,
 wherein a target disease is a disease caused by excess uptake
 of at least a kind of carbohydrate selected from glucose, fructose
 25 and mannose.


6. A pharmaceutical composition as claimed in claim 5, wherein

the target disease is selected from a group consisting of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorders, atherosclerosis, hypertension, congestive heart failure, edematous state, metabolic acidosis, syndrome X, hyperuricemia, gout and nephritis.

7. A pharmaceutical composition as claimed in any one of claims 3 to 6, which comprises at least one drug selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an

N-acetylated- α -linked-acid-dipeptidase inhibitor,
 insulin-like growth factor-I, platelet-derived growth factor,
 a platelet-derived growth factor analogue, epidermal growth
 factor, nerve growth factor, a carnitine derivative, uridine,
 5 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide,
 Y-128, a hydroxymethylglutaryl coenzyme A reductase inhibitor,
 a fibric acid derivative, a β_3 -adrenoceptor agonist, an
 acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol,
 a thyroid hormone receptor agonist, a cholesterol absorption
 10 inhibitor, a lipase inhibitor, a microsomal triglyceride
 transfer protein inhibitor, a lipoxygenase inhibitor, a
 carnitine palmitoyl-transferase inhibitor, a squalene synthase
 inhibitor, a low-density lipoprotein receptor enhancer, a
 nicotinic acid derivative, a bile acid sequestrant, a sodium/bile
 15 acid cotransporter inhibitor, a cholesterol ester transfer
 protein inhibitor, an appetite suppressant, an
 angiotensin-converting enzyme inhibitor, a neutral
 endopeptidase inhibitor, an angiotensin II receptor antagonist,
 an endothelin-converting enzyme inhibitor, an endothelin
 20 receptor antagonist, a diuretic agent, a calcium antagonist,
 a vasodilating antihypertensive agent, a sympathetic blocking
 agent, a centrally acting antihypertensive agent, an
 α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid
 synthesis inhibitor, a uricosuric agent and a urinary
 25 alkalinizer.


8. A pyrazole derivative represented by the general formula:



wherein

R^{1A} represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^A and T^A represents a group selected from



which has a protective group, and the other represents a group represented by the formula: $-Z^A-Ar^A$ wherein Ar^A represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C_{1-9}

heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and Z^A represents -O-, -S- or - NY^A - (in which Y^A represents a hydrogen atom, a C_{1-6} alkyl group or a protective group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or an aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$,

-C(=O)N(G^{2B})₂, -S(=O)₂G^{2A}, -S(=O)₂OG^{2A}, -S(=O)₂N(G^{2B})₂, -S(=O)G^{1A},
 -OC(=O)G^{1A}, -OC(=O)N(G^{2B})₂, -NHC(=O)G^{2A}, -OS(=O)₂G^{1A}, -NHS(=O)₂G^{1A}
 and -C(=O)NHS(=O)₂G^{1A};

in the above substituent group (A1) and/or (B1),

5 G^{1A} represents a C₁₋₆ alkyl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 group (C1), a C₂₋₆ alkenyl group which may have the same or different
 1 to 3 groups selected from the following substituent group (C1),
 a C₂₋₆ alkynyl group which may have the same or different 1 to
 10 3 groups selected from the following substituent group (C1),
 a C₃₋₈ cycloalkyl group which may have the same or different 1
 to 3 groups selected from the following substituent group (C1),
 a C₆₋₁₀ aryl group which may have the same or different 1 to 3
 groups selected from the following substituent group (D1), a
 15 C₂₋₉ heterocycloalkyl group which may have the same or different
 1 to 3 groups selected from the following substituent group (C1),
 or a C₁₋₉ heteroaryl group which may have the same or different
 1 to 3 groups selected from the following substituent group (D1);

 G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which
 20 may have the same or different 1 to 3 groups selected from the
 following substituent group (C1), a C₂₋₆ alkenyl group which may
 have the same or different 1 to 3 groups selected from the following
 substituent group (C1), a C₂₋₆ alkynyl group which may have the
 same or different 1 to 3 groups selected from the following
 25 substituent group (C1), a C₃₋₈ cycloalkyl group which may have
 the same or different 1 to 3 groups selected from the following
 substituent group (C1), a C₆₋₁₀ aryl group which may have the

same or different 1 to 3 groups selected from the following
 substituent group (D1), a C₂₋₉ heterocycloalkyl group which may
 have the same or different 1 to 3 groups selected from the following
 substituent group (C1), or a C₁₋₉ heteroaryl group which may have
 5 the same or different 1 to 3 groups selected from the following
 substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C₁₋₆
 alkyl group which may have the same or different 1 to 3 groups
 selected from the following substituent group (C1), a C₂₋₆ alkenyl
 10 group which may have the same or different 1 to 3 groups selected
 from the following substituent group (C1), a C₂₋₆ alkynyl group
 which may have the same or different 1 to 3 groups selected from
 the following substituent group (C1), a C₃₋₈ cycloalkyl group
 which may have the same or different 1 to 3 groups selected from
 15 the following substituent group (C1), a C₆₋₁₀ aryl group which
 may have the same or different 1 to 3 groups selected from the
 following substituent group (D1), a C₂₋₉ heterocycloalkyl group
 which may have the same or different 1 to 3 groups selected from
 the following substituent group (C1), or a C₁₋₉ heteroaryl group
 20 which may have the same or different 1 to 3 groups selected from
 the following substituent group (D1); and with the proviso that
 G^{2B} may be the same or different when there are 2 or more G^{2B}
 in the substituents;

G³ represents a C₁₋₆ alkyl group;

25 G^{4A} represents a C₁₋₆ alkyl group which may have the same
 or different 1 to 3 groups selected from the following substituent
 group (C1), and with the proviso that G^{4A} may be the same or

different when there are 2 or more G^{4A} in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group,
 $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$,
 5 $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$,
 $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and
 $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$,
 10 $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$,
 $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$,
 $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;


in the substituent group (C1) and/or (D1),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a
 15 C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9}
 heterocycloalkyl group or a C_{1-9} heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6}
 alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10}
 aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl
 20 group;

G^{6A} represents a protective group, a hydrogen atom, a C_{1-6}
 alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl
 group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9}
 heteroaryl group, and with the proviso that G^{6A} may be the same
 25 or different when there are 2 or more G^{6A} in the substituents,
 or a pharmaceutically acceptable salt thereof.

9. A pyrazole derivative represented by the general formula:



wherein

R^{1A} represents a hydrogen atom, a C_{1-6} alkyl group which
 5 may have the same or different 1 to 3 groups selected from the
 following substituent group (A1), a C_{2-6} alkenyl group which may
 have the same or different 1 to 3 groups selected from the following
 substituent group (A1), a C_{2-6} alkynyl group which may have the
 same or different 1 to 3 groups selected from the following
 10 substituent group (A1), a C_{3-8} cycloalkyl group which may have
 the same or different 1 to 3 groups selected from the following
 substituent group (A1), a C_{6-10} aryl group which may have the
 same or different 1 to 3 groups selected from the following
 substituent group (B1), a C_{2-9} heterocycloalkyl group which may
 15 have the same or different 1 to 3 groups selected from the following
 substituent group (A1), or a C_{1-9} heteroaryl group which may have
 the same or different 1 to 3 groups selected from the following
 substituent group (B1);

one of Q^B and T^B represents a hydroxy group, and the other
 20 represents a group represented by the formula: $-Z^A-Ar^A$ wherein
 Ar^A represents a C_{6-10} aryl group which may have the same or different
 1 to 3 groups selected from the following substituent group (B1)
 or a C_{1-9} heteroaryl group which may have the same or different
 1 to 3 groups selected from the following substituent group (B1);
 25 and Z^A represents $-O-$, $-S-$ or $-NY^A-$ (in which Y^A represents a

hydrogen atom, a C₁₋₆ alkyl group or a protective group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or an aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G^{1A}, -OG^{2B}, -SG^{2B}, -N(G^{2B})₂, -C(=O)G^{2A}, -C(=O)OG^{2B}, -C(=O)N(G^{2B})₂, -S(=O)₂G^{2A}, -S(=O)₂OG^{2A}, -S(=O)₂N(G^{2B})₂, -S(=O)G^{1A}, -OC(=O)G^{1A}, -OC(=O)N(G^{2B})₂, -NHC(=O)G^{2A}, -OS(=O)₂G^{1A}, -NHS(=O)₂G^{1A} and -C(=O)NHS(=O)₂G^{1A};

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, -G^{1A}, -OG^{2B}, -SG^{2B}, -N(G^{2B})₂, -G³OG^{4A}, -G³N(G^{4A})₂, -C(=O)G^{2A}, -C(=O)OG^{2B}, -C(=O)N(G^{2B})₂, -S(=O)₂G^{2A}, -S(=O)₂OG^{2A}, -S(=O)₂N(G^{2B})₂, -S(=O)G^{1A}, -OC(=O)G^{1A}, -OC(=O)N(G^{2B})₂, -NHC(=O)G^{2A}, -OS(=O)₂G^{1A}, -NHS(=O)₂G^{1A} and -C(=O)NHS(=O)₂G^{1A};

in the above substituent group (A1) and/or (B1),

G^{1A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following

substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1); and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G³ represents a C₁₋₆ alkyl group;

G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents; [substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group,

-G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂,
 -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵,
 -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and
 -C(=O)NHS(=O)₂G⁵; and

5 [substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG^{6A},
 -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶,
 -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂,
 -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵;

10 in the substituent group (C1) and/or (D1),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a
 C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉
 heterocycloalkyl group or a C₁₋₉ heteroaryl group;

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆
 15 alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀
 aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl
 group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆
 alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl
 20 group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉
 heteroaryl group, and with the proviso that G^{6A} may be the same
 or different when there are 2 or more G^{6A} in the substituents,
 or a pharmaceutically acceptable salt thereof.